Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 2013; 110(05): 857-858
DOI: 10.1160/TH13-09-0805
DOI: 10.1160/TH13-09-0805
Theme Issue Editorial
The Platelet – Thrombosis and Beyond
Further Information
Publication History
Received: 01 October 2013
Accepted after major revision: 02 October 2013
Publication Date:
01 December 2017 (online)
-
References
- 1 Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2008; 99: 480-486.
- 2 Nachman RL, Rafii S. Platelets, petechiae, and preservation of the vascular wall. N Engl J Med 2008; 359: 1261-1270.
- 3 Geisler T, Grass D, Bigalke B. et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61.
- 4 Serebruany VL. Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel. Thromb Haemost 2012; 108: 1024-1027.
- 5 Serebruany VL, Atar D. Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials–common patterns in TRITON, RECORD, and PLATO? Thromb Haemost 2012; 108: 412-414.
- 6 Verheugt FW. Outcomes of positive randomised controlled clinical trials: double-blind or double vision? Editorial on Serebruany, Atar: 'Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials–common patterns in TRITON, RECORD, and PLATO?' (Thromb Haemost 2012; 108.3). Thromb Haemost 2012; 108: 410-411.
- 7 Aradi D, Kuliczkowski W, Atar D. et al. Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thromb Haemost 2012; 107: 338-345.
- 8 Serebruany VL. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105: 752-759.
- 9 Ohman EM, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). Thromb Haemost 2011; 105: 763-710.
- 10 MacFadyen J, Jackson S. Differentiating hemostasis from thrombosis for therapeutic benefit. Thromb Haemost 2013; 110: 859-867.
- 11 Ungerer M, Münch G. Novel antiplatelet drugs in clinical development. Thromb Haemost 2013; 110: 868-875.
- 12 Geisler T, Gawaz M. Genetic variation of platelet function and pharmacology: Update of current knowledge. Thromb Haemost 2013; 110: 876-887.
- 13 Langer HF, Haubner R, Pichler BJ. et al. Radionuclide imaging: a molecular key to the atherosclerotic plaque. J Am Coll Cardiol 2008; 52: 1-12.
- 14 Libby P, Ridker PM, Hansson GK. Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138.
- 15 Langer HF, Choi EY, Zhou H. et al. Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis. Circ Res 2012; 110: 1202-1210.
- 16 Langer H, Chavakis T. Platelets and neurovascular inflammation. Thromb Haemost 2013; 110: 888-893.
- 17 Karshovska E, Weber C, von Hundelshausen P. Platelet chemokines in health and disease. Thromb Haemost 2013; 110: 894-902.
- 18 Seizer P, May A. Platelets and matrix metalloproteinases. Thromb Haemost 2013; 110: 903-909.
- 19 Strüßmann T, Tillmann S, Wirtz T. et al. Platelets are a previously unrecognized source of MIF. Thromb Haemost 2013; 110: 1004-1013.
- 20 Verschoor A, Langer H. Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost 2013; 110: 919-919.
- 21 Krämer B, Weyrich A, Lindemann S. Protein degradation systems in platelets. Thromb Haemost 2013; 110: 920-924.
- 22 Lang F, Muenzer P, Gawaz M. et al. Regulation of STIM1/Orai1-dependent Ca2+ Signaling in Platelets. Thromb Haemost 2013; 110: 925-930.